State of Wyoming Increases Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• The State of Wyoming increased its stake in AMNEAL PHARMACEUTICALS by 112.7%, holding 81,772 shares worth approximately $685,000 after acquiring 43,320 additional shares in the first quarter.
• Several large investors, including Janney Montgomery Scott LLC and Allspring Global Investments, have also raised their positions in AMNEAL PHARMACEUTICALS, indicating growing institutional interest in the company.
• AMNEAL PHARMACEUTICALS reported $0.23 earnings per share for the last quarter, surpassing the estimate of $0.17, and set a fiscal year 2025 EPS guidance between 0.700-0.750.

State of Wyoming grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 112.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,772 shares of the company's stock after acquiring an additional 43,320 shares during the quarter. State of Wyoming's holdings in Amneal Pharmaceuticals were worth $685,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of AMRX. GAMMA Investing LLC grew its holdings in shares of Amneal Pharmaceuticals by 5,975.0% during the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after buying an additional 3,107 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Amneal Pharmaceuticals during the first quarter worth about $31,000. Amalgamated Bank grew its holdings in shares of Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $52,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth about $107,000. 31.82% of the stock is owned by institutional investors.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Andrew S. Boyer sold 279,244 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president directly owned 152,426 shares of the company's stock, valued at approximately $1,429,755.88. This represents a 64.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Kiely sold 32,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total value of $295,360.00. Following the transaction, the director owned 225,433 shares of the company's stock, valued at $2,080,746.59. This trade represents a 12.43% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 609,206 shares of company stock worth $5,700,625. 17.45% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on AMRX. The Goldman Sachs Group began coverage on Amneal Pharmaceuticals in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Wall Street Zen downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ:AMRX traded down $0.03 on Wednesday, reaching $9.56. 621,360 shares of the company's stock were exchanged, compared to its average volume of 1,670,611. The company has a fifty day moving average of $8.59 and a 200-day moving average of $8.09. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $9.79. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of 956.46 and a beta of 1.19.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.